Drug Trial Radar · NCT06063109
A Clinical Trial to Evaluate the Safety and the Pharmacokinetic Interaction of Telmisartan and Dapagliflozin.
Last checked: Nov 19, 2026Latest source record: Nov 22, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
51
Actual
Start
Oct 9, 2023
Primary completion
Nov 9, 2023
Study completion Nov 9, 2023
Sponsor
- Lead sponsor
- THPharm Corp.Industry
- Sponsor type
- Industry
- First posted
- Oct 2, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The study was designed to evaluate the safety and pharmacokinetic interaction between THP-00101 and THP-00102 in healthy adult volunteers.
Conditions
- Hypertension
- Diabetes Mellitus, Type 2
Interventions
THP-00101 (Dapagliflozin) 10mgDrug
Dapagliflozin 10mg Tablet / 5 days in period 1 and period 2 will be given to Arm A Dapagliflozin 10mg Tablet / 5 days in period 2 will be given to Arm B
THP-00102 (Telmisartan) 80mgDrug
Telmisartan 80mg Tablet / 5 days in period 1 and period 2 will be given to Arm B Telmisartan 80mg Tablet / 5 days in period 2 will be given to Arm A
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetics - AUCτ,ssTime frame: Day 1 to Day 11
- Pharmacokinetics - Cmax,ssTime frame: Day 1 to Day 11
- Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]Time frame: Day 1 to Day 17
Locations
1 site in 1 country. Site status is shown where the registry gives one.
H Plus Yangji Hospital
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.